EUCTR2009-017251-94-FI进行中（未招募）不适用
Efficacy and safety of BF2.649 in the treatment of Excessive Daytime Sleepiness in patients with Obstructive Sleep Apnoea syndrome (OSA), refusing the nasal continuous positive airway pressure (nCPAP) therapy - HAROSA II
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- Bioprojet
- 入组人数
- 280
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Male and/or female outpatients aged from at least 18 years of age
- •? Polysomnography (a description of full night polysomnography is detailed in appendix 3) performed between V1 and V2 or during the last twelve months with:. Apnoea-Hypopnoea Index (AHI) ? 15
- •Periodic Limb Movement Disorders as defined by by PLM Arousal Index (PLMAI) ? 10
- •? Patients refusing to be treated by nCPAP therapy, and still complaining of Excessive Daytime Sleepiness
- •? Epworth Sleepiness scale = 12
- •? Beck Depression Inventory 13 items (BDI-13 items): score < 16 and item G = 0
- •? Mini Mental State Examination (MMSE) ? 28 (an example of MMSE14 questionnaire is provided in Appendix 9)
- •? Body Mass Index (BMI) ? 40 Kg/m2
- •? Female patients with child-bearing potential using a medically accepted method of birth control, (i.e. oral contraceptives of normal average dosage) agreeing to continue this method throughout the study, and during the month following treatment discontinuation, being negative to the serum pregnancy test performed at the screening visit
- •? If specified by the investigator, the patient must be willing not to operate a car (if sleepy at wheel) or heavy machinery for the duration of the trial, or as long as the investigator deems it clinically indicated. In addition, patients should be willing to maintain during the study their usual behaviours which could affect their diurnal sleepiness (e.g. circadian rhythm, caffeine consumption, nocturnal sleep duration).
- •? Patients having signed and dated the informed consent form
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •? Patient without OSA, suffering from chronic severe insomnia in accordance with the International Classification of Sleep Disorders (ICSD 2005) without OSA.
- •? Patient with co-existing narcolepsy (ICSD 2005), judged on clinical criteria
- •? Patient with sleep debt not due to OSA (according to physician?s judgment)
- •? Patient with non respiratory sleep fragmentation (restless legs syndrome…)
- •? Shift work - professional drivers
- •? Refusal from the patient to stop any current therapy for excessive daytime sleepiness, or predictable risks for the patient to stop the therapy
- •? Patient suffering from a psychiatric disease
- •? Acute or chronic disease that could bother the appreciation of improvement in EDS (i.e. COPD…)
- •? Current or recent (within one year) history of drug, alcohol, narcotic or other substance or dependence.
- •? Patient with a dominant arm deficiency impeding the achievement of the tests
- •? Any significant serious abnormality of the cardiovascular system, e.g. recent myocardial infarction, angina, hypertension or dysrhythmias (within the previous 6 months), Electrocardiogram Bazett?s corrected QT interval higher than 450 ms, history of left ventricular hypertrophy or mitral valve prolapse
- •? Severe co-morbid medical or biological conditions that may jeopardize the study participation, at the discretion of the investigator ( particularly, in the cardiovascular system and instable diabetes)
- •? Positive serology tests (optional HIV–HCV–HBsAg)
- •? Pregnant or breast-feeding women
- •Women with child-bearing potential and no efficient birth-control method
- •? Patient unable to understand the study protocol
- •? Patient with suspected or known hypersensibility to study medication
- •? Patient with a dominant arm deficiency impeding the achievement of the test
- •? Patient using prohibited treatments
- •? Patient participating to another study, or being in a follow-up period in another study
- •Congenital galactose poisoining, glucose and galactose malabsorption, deficit in
研究者
相似试验
进行中（未招募）
不适用
The study aims to confirm the effectiveness and safety of BF2.649 over placebo for the treatment of excessive daytime sleepiness associated with Obstructive Sleep Apnoea syndrome in patients who refuse CPAP therapyExcessive diurnal sleepiness in patients with moderate to severe Obstructive Sleep Apnoea (OSA) refusing the nasal Continuous Positive Airway Pressure (nCPAP) therapyMedDRA version: 14.1Level: LLTClassification code 10015595Term: Excessive daytime sleepinessSystem Organ Class: 100000004852EUCTR2009-017251-94-BGBioprojet280
进行中（未招募）
不适用
The study aims to confirm the effectiveness and safety of BF2.649 over placebo for the treatment of excessive daytime sleepiness associated with Obstructive Sleep Apnoea syndrome in patients who refuse CPAP therapyExcessive diurnal sleepiness in patients with moderate to severe Obstructive Sleep Apnoea (OSA) refusing the nasal Continuous Positive Airway Pressure (nCPAP) therapyMedDRA version: 14.1Level: LLTClassification code 10015595Term: Excessive daytime sleepinessSystem Organ Class: 10029205 - Nervous system disordersEUCTR2009-017251-94-DKBioprojet280
进行中（未招募）
不适用
The study aims to confirm the effectiveness and safety of BF2.649 over placebo for the treatment of excessive daytime sleepiness associated with Obstructive Sleep Apnoea syndrome in patients who refuse CPAP therapyExcessive diurnal sleepiness in patients with moderate to severe Obstructive Sleep Apnoea (OSA) refusing the nasal Continuous Positive Airway Pressure (nCPAP) therapyMedDRA version: 14.1Level: LLTClassification code 10015595Term: Excessive daytime sleepinessSystem Organ Class: 10029205 - Nervous system disordersEUCTR2009-017251-94-SEBioprojet280
进行中（未招募）
不适用
The study aims to confirm the effectiveness and safety of BF2.649 over placebo for the treatment of excessive daytime sleepiness associated with Obstructive Sleep Apnoea syndrome in patients who refuse CPAP therapyExcessive diurnal sleepiness in patients with moderate to severe Obstructive Sleep Apnoea (OSA) refusing the nasal Continuous Positive Airway Pressure (nCPAP) therapyMedDRA version: 14.1Level: LLTClassification code 10015595Term: Excessive daytime sleepinessSystem Organ Class: 100000004852EUCTR2009-017251-94-DEBioprojet280
进行中（未招募）
1 期
The study aims to confirm the effectiveness and safety of BF2.649 over placebo for the treatment of excessive daytime sleepiness associated with Obstructive Sleep Apnoea syndrome in patients who refuse CPAP therapyExcessive diurnal sleepiness in patients with moderate to severe Obstructive Sleep Apnoea (OSA) refusing the nasal Continuous Positive Airway Pressure (nCPAP) therapyMedDRA version: 13.1Level: LLTClassification code 10015595Term: Excessive daytime sleepinessSystem Organ Class: 10029205 - Nervous system disordersEUCTR2009-017251-94-BEBioprojet268